Helix BioPharma (TSE:HBP) has released an update.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has begun trading on the Frankfurt Boerse, aiming to broaden its shareholder base and enhance international financing opportunities. This strategic move is expected to attract European investors and support the company’s efforts in developing cancer treatments.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
